FAPI-PET shows promise for detecting pancreatic cancer

In this study, the researchers analyzed data on 62 patients with suspected pancreatic cancer. In addition to Ga-68 FAPI-PET imaging, all patients also underwent contrast-enhanced CT, and 38 underwent F-18 FDG-PET. The primary endpoint was the association between Ga-FAPI-PET radiotracer maximum standardized uptake value (SUVmax) and histopathologic FAP expression, while secondary endpoints included comparisons to standard imaging.A male patient with suspected recurrent pancreatic cancer. Contrast-enhanced CT shows mass around superior mesenteric artery after pancreatectomy. F-18 FDG only shows discrete uptake of lesion (SUVmax, 3.8), whereas Ga-68 FAPI clearly visualizes recurrent tumor. Patient received adjuvant chemotherapy after Ga-68 FAPI. Patient denied recommended chemotherapy. Increase of CA19-9 levels (from 240 U/mL to 767 U/mL) and follow-up imaging eight months later validated progression of mesenteric mass as well as increased F-18 FDG uptake (SUVmax, 5.3). Image courtesy of the Journal of Nuclear Medicine.The primary endpoint was met, according to the findings. The association between Ga-68 FAPI SUVmax in pancreatic tumors and histopathologic FAP expression determined in lab tests was significant, with a Spearman correlation coefficient of 0.48 (p = 0.04).In addition, in a head-to-head comparison versus F-18 FDG-PET or contrast-enhanced CT, 346 lesions were detected by any modality, with the highest detection by Ga-68 FAPI-PET/CT. .tg {border-collapse:collapse;b...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Nuclear Radiology Source Type: news